Generali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
Doverie is one of the largest private health insurance companies in Bulgaria. As one of the first health insurance funds in the country, it ranked among the top three in 2024 by premium revenue.
Generali, the Italian insurance company and one of the world’s leading insurance providers, has acquired Doverie as part of its growth strategy in the Central and Eastern Europe (CEE) region. With this acquisition, Generali will become the second-largest player in Bulgaria’s health insurance market.
Doverie United Holding is a renowned publicly listed equity fund in Bulgaria, with a diverse portfolio that includes 18 companies across eight economic sectors.
Oaklins’ team in Bulgaria acted as the exclusive sell-side M&A adviser to Doverie United Holding, assisting the client throughout the entire divestment process.
We are now delighted that, with this transaction, Doverie has found in Generali the strategic partner that can continue the development trajectory of the business and bring it to the next level of growth. We are also thankful to Oaklins’ Bulgarian team for its professionalism and dedication throughout the deal. They were instrumental in managing the relationship between all the stakeholders, the negotiation process and the execution of the transaction.”
Alexander Hristov
CEO, Doverie United Holding
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreCenterbridge Partners has announced a minority interest investment in Pure Cremation
Centerbridge Partners, L.P. has announced a structured minority interest investment in Pure Cremation. The investment includes both loan and equity instruments and is subject to regulatory approval, with completion expected in the first half of 2026.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more